RATIONALE-312

NCT04005716 📎

Regimen

Experimental
tislelizumab + etoposide + carboplatin or cisplatin
Control
placebo + etoposide + carboplatin or cisplatin

Population

Previously untreated extensive-stage small-cell lung cancer (Chinese population)

Key finding

mOS 15.5 vs 13.5 mo (HR 0.75, 95% CI 0.61-0.93, one-sided P=0.0040); mPFS 4.7 vs 4.3 mo (HR 0.64, 95% CI 0.52-0.78, P<0.0001)

Source: PMID 38460751

Timeline

    Guideline citations

    • CSCO SCLC 2025 (p.65)⚠️ OCR source